LONDON, December 8, 2017 /PRNewswire/ --
Forecasts and Analysis by Therapeutics (GFT 505, Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region
Read on to discover how this definitive report can transform your own research and save you time.
The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.
• 132 quantitative tables, charts, and graphs across 145 pages
• Global NASH market outlook and analysis from to 2027
• Global NASH submarket forecasts and analysis from to 2027
• GFT 505
• Obeticholic Acid (INT-747)
• Simtuzumab and Liraglutide (Victoza)
• Vitamin E
• Regional and National NASH market forecasts to 2027
• North America forecast to 2027:
• US forecast to 2027
• Canada forecast to 2027
• Mexico forecast to 2027
• South America forecast to 2027:
• Brazil forecast to 2027
• Argentina forecast to 2027
• Paraguay forecast to 2027
• Bolivia forecast to 2027
• Rest of South America forecast to 2027
• Europe forecast to 2027:
• Germany forecast to 2027
• UK forecast to 2027
• France forecast to 2027
• Italy forecast to 2027
• Spain forecast to 2027
• Rest of Europe forecast to 2027
• Asia-Pacific forecast to 2027
• Japan forecast to 2027
• India forecast to 2027
• China forecast to 2027
• Australia forecast to 2027
• Thailand forecast to 2027
• Rest of Asia-Pacific forecast to 2027
• Rest of World forecast to 2027:
• Middle East forecast to 2027
• Africa forecast to 2027
• Other Countries forecast to 2027
Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH)
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
• Leading Pharmaceutical companies
• R&D staff
• Business development managers
To request a report overview of this report please contact Sara Peerun at [email protected] (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2071/Nonalcoholic-Steatohepatitis-(NASH)-Market-Report-to-2027
Companies Mentioned in the Report
Amarin Corp. Plc
Array BioPharma, Inc.
Associates Of Cape Cod Inc.
Astex Pharmaceuticals Inc.
Bayer HealthCare AG
Bayer Schering Pharma Aktiengesellschaft
BioLife Solutions, Inc.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Co.
Cardinal Health, Inc.
Chugai Pharmaceutical Co., Ltd.
CK Life Sciences International (Holdings), Inc.
Consensys Imaging Service Inc.
Cornerstone Research & Development Inc.
Crescendo Bioscience, Inc.
CTI BioPharma Corp.
Deroyal Industries Inc.
Domain Therapeutics SA
Emd Millipore Corporation
Emd Serono Inc.
Endo International Plc
Galmed Pharmaceuticals Ltd.
GE HEALTHCARE LTD
Gilead Sciences, Inc.
Henry Schein, Inc.
Intercept Pharmaceuticals, Inc.
Janssen Biotech, Inc.
JHL Biotech, Inc.
Johnson & Johnson
Laboratory Corp. of America Holdings
Lombard Medical, Inc.
Lonza Group AG
Medline Industries Inc.
Merck & Co., Inc.
Motion Picture And Television Fund
Myriad Genetics, Inc.
National Cancer Institute
Nexvet Biopharma PLC
Northwell Health Inc.
Novo Nordisk AG
Opexa Therapeutics, Inc.
Otsuka Pharmaceutical Co. Ltd.
Owens & Minor, Inc.
Panacos Pharmaceuticals, Inc.
PELICAN HEALTHCARE LTD
Polymer Technology Systems Inc.
Quest Diagnostics, Inc.
Smith & Nephew Plc
Vertex Pharmaceuticals, Inc.
Windtree Therapeutics, Inc.
To see a report overview please email Sara Peerun on [email protected]